1H magnetic resonance spectroscopy of prostate cancer: Biomarkers for tumor characterization

Cancer Biomarkers

Volumn 4, Issue 4-5, 2008, Pages 263-276

  Zakian, Kristen L ^a   Shukla Dave, Amita ^a   Ackerstaff, Ellen ^a   Hricak, Hedvig ^a   Koutcher, Jason A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Choline; Detection; Gleason score; Magnetic resonance; Prostate cancer; Proton; Spectroscopy

Indexed keywords

CHOLINE DERIVATIVE; CITRIC ACID; POLYAMINE DERIVATIVE; TUMOR MARKER; CHOLINE; POLYAMINE;

CANCER CELL; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CELL DENSITY; CELL METABOLISM; CELL PROLIFERATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; IMAGE DISPLAY; IMAGE PROCESSING; IMAGE QUALITY; IN VITRO STUDY; IN VIVO STUDY; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT CARE PLANNING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITATIVE DIAGNOSIS; QUANTITATIVE DIAGNOSIS; REVIEW; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; STANDARDIZATION; THREE DIMENSIONAL IMAGING; TISSUE CHARACTERIZATION; MALE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROSTATE TUMOR;

CHOLINE; CITRATES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; POLYAMINES; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 54949137302     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2008-44-508     Document Type: Review

References (60)

1. E. Ackerstaff, B. Gimi, D. Artemov and Z.M. Bhujwalla, Anti-inflammatory Agent Indomethacin Reduces Invasion and Causes Metabolic Changes in a Human Breast Cancer Cell Line, Neoplasia 9(12) (Dec 2007), 1138-1151.
2. E. Ackerstaff, K. Glunde and Z.M. Bhujwalla, Choline phospholipid metabolism: A target in cancer cells? Journal of Cellular Biochemistry 90(3) (2003), 525-533.
3. E. Ackerstaff, B.R. Pflug, J.B. Nelson and Z.M. Bhujwalla, Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells, Cancer Research 61(9) (2001), 3599-3603.
4. H. Augustin, P.G. Hammerer, M. Graefen, J. Palisaar, F. Daghofer and H. Huland, A Erbersdobler. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy, J Cancer Res Clin Oncol 129(11) (2003), 662-668.
5. P.G. Borboroglu, S.W. Comer, R.H. Riffenburgh and C.L. Amling, Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies, J Urol 163(1) (2000), 158-162.
6. P. Bottomley, Selective volume method for performing localized NMR spectroscopy. USA patent 4,480,228. 1984.
7. L. Breiman, J. Friedman, C.J. Stone and R.A. Oshen, Classification and Regression Trees, Belmont, CA: Chapman and Hall, 1984.
8. T.R. Brown, B.M. Kincaid and K. Ugurbil, NMR Chemical Shift Imaging in Three Dimensions, PNAS 79(11) (1982), 3523-3526.
9. G.M. Bydder, J.M. Pennock, R.E. Steiner, S. Khenia, J.A. Payne and I.R. Young, The short TI inversion recovery sequence - an approach to MR imaging of the abdomen, Magn Reson Imaging 3(3) (1985), 251-254.
10. A.P. Chen, C.H. Cunningham, J. Kurhanewicz, D. Xu, R.E. Hurd, J.M. Pauly, L. Carvajal, K. Karpodinis and D.B. Vigneron, High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the NILEV-PRESS sequence, Magn Reson Imaging 24(7) (2006), 825-832.
11. L.L. Cheng, C. Wu, M.R. Smith and R.G. Gonzalez, Non-destructive quantitation of spermine in huma prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T, FEBS Lett 494(1-2) (2001), 112-116.
12. 31P Magnetic Resonance Spectroscopy, J Urol 150(6) (1993), 2019-2024.
13. S.J. DiBiase, K. Hosseinzadek R.P. Gullapalli, S.C. Jacobs, M.J. Naslund, G.N. Sklar, R.B. Alexander and C. Yu, Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer, Int J Radiat Oncol Biol Phys 52(2) (2002), 429-438.
14. B. Djavan and M. Margreiter, Biopsy standards for detection of prostate cancer, World J Urol 25(1) (2007), 11-17.
15. L.E. Eichelberger, M.O. Kock J.K. Daggy, T.M. Ulbright, J.N. Eble and L. Cheng, Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer, Am J Clin Pathol 120(3) (2003), 386-391.
16. A.H. Fowler, A.A. Pappas, J.C. Holder, A.E. Finkbeiner, G.V. Dalrymple, M.S. Mullins, J.R. Sprigg and R.A. Komoroski, Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR, Magn Reson Med 25(1) (1992), 140-147.
17. J. Frahm, H. Bruhn, M.N.L. Gyngell, K.D. Merboldt, W. Hanicke and R. Sauter, Localized High-resolution Proton NMR Spectroscopy Using Stimulated Echoes: Initial Applications to Human Brain in Vivo, Magn Reson Med 9(1) (1989), 79-93.
18. J.J. Futterer, T.W. Scheenen, S.W. Heijmink, H.J. Huisman, C.A. Hulsbergen-Van de Kaa, J.A. Witjes, A. Heerschap and J.O. Barentsz, Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate, Invest Radiol 42(2) (2007), 116-122.
19. J.J. Futterer, T.W. Scheenen, H.J. Huisman, D.W. Klomp, F.A. van Dorsten, C.A. Hulsbergen-van de Kaa, J.A. Witjes, A. Heerschap and J.O. Barentsz. Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate, Invest Radiol 39(11) (2004), 671-680.
20. D.F. Gleason, VACU Group. Histologic Grading and Clinical Staging of Prostatic CarcinoTa, in: Urologic Pathology: the Prostate, M. Tannebaum, ed., Philadelphia: Lea and Febiger, 1977, pp. 171-197.
21. K. Glunde, E. Ackerstaff, N. Mori, M.A. Jacobs and Z.M. Bhujwalla, Choline phospholipid metabolism in cancer: Consequences for molecular pharmaceutical interventions, Molecular Pharmaceutics 3(5) (2006), 496-506.
22. A. Haase, J. Frahm, W. Hanicke and D. Matthaei, 1H NMR Chemical Shift Selective (CHESS) Imaging, Phys Med Biol 30 (1985), 341-344.
23. M. Han, P.B. Snow, J.I. Epstein, T.Y. Chan, K.A. Jones, P.C. Walsh and A.W. Partin, A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy, Urology 56(6) (2000), 994-999.
24. A. Heerschap, G.J. Jager, M. van der Graaf, J.O. Barentsz, J.J. de la Rosette, G.O. Oosterhof, E.T. Ruijter and S.H. Ruijs, In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue, Anticancer Res 17(3A) (1997), 1455-1460.
25. C.M. Herman, M.W. Kattan, M. Ohori, P.T. Scardino and T.M. Wheeler, Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: A multivariate analysis of 823 men treated with radical prostatectomy, Am J Surg Pathol 25(5) (2001), 657-660.
26. J.A. Jung, F.V. Coakley, D.B. Vigneron, M.G. Swanson, A. Qayyum, V. Weinberg, K.D. Jones, P.R. Carroll and J. Kurhanewicz, Prostate depiction at endorectal MR spectroscopic imaging: Investigation of a standardized evaluation system, Radiology 233(3) (2904), 701-708.
27. Y. Kaji, J. Kurhanewicz, H. Hricak, D.L. Sokolov, L.R. Huang, S.J. Nelson and D.B. Vigneron, Localizing Prostate Cancer in the Presence of Postbiopsy Changes on MR Images: Role of Proton MR Spectroscopic Imaging, Radiology 206(3) (1998), 785-790.
28. 1H Magnetic Resonance Spectroscopy and Biochemical Study, Magn Reson Med 29(2) (1993), 149-157.
29. J. Kurhanewicz, D.B. Vigneron, H. Hricak, P. Narayan, P. Carroll and S.J. Nelson, Three-dimensional H-1 MR Spectroscopic Imaging of the in Situ Human Prostate with High (0.24-0.7-cm&3) Spatial Resolution, Radiology 198(3) (1996), 795-805.
30. J. Kurhanewicz, D.B. Vigneron, H. Hricak, F. Parivar, S.J. Nelson, K. Shinohara and P.R. Carroll, Prostate Cancer: Metabolic Response to Cryosurgery as Detected with 3D H-1 MR Spectroscopic Imaging, Radiology 200(2) (1996), 489-496.
31. J. Kurhanewicz, D.B. Vigneron, S.J. Nelson and H. Hricak, Citrate as an in vivo Marker to Discriminate Prostate Cancer from Benign Prostatic Hyperplasia and Normal Prostate Peripheral Zone: Detection via Localized Proton Spectroscopy, Urology 45(3) (1995), 459-466.
32. R. Males, D. Vigneron, J. Star-Lack, S. Falbo, S. Nelson, H. Hricak and J. Kurhanewicz, Clinical application of BASING and spectral/spatial water and hpid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging, Magn Reson Med 43(1) (2000), 17-22.
33. J.E. McNeal, E.A. Redwine, F.S. Freiha and T.A. Stamey, Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread, Am J Surg Pathol 12(12) (1988), 897-906.
34. U.G. Mueller-Lisse, D.B. Vigneron, H. Hricak, M.G. Swanson, P.R. Carroll, A. Bessette, J. Scheidler, A. Srivastava, R.G. Males, I. Cha and J. Kurhanewicz, Localized prostate cancer: Effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: Clinicopathologic case-controlied study, Radiology 221(2) (2001), 380-390.
35. P. Narayan, P. Jajodia, J. Kurhanewicz, A. Thomas, J. MacDonald, B. Hubesch, M. Hedgcock, C.M. Anderson, T.L. James, E.A. Tanagho et al., Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using transrectal 31 phosphorus magnetic resonance spectroscopy: A preliminary report, J Urol 146(1) (1991), 66-74.
36. A.P. Pathak, B. Gimi, K. Glunde, E. Ackerstaff, D. Artemov and Z.M. Bhujwalla, Molecular and functional imaging of cancer: Advances in MRI and MRS, Methods in Enzymology 386 (2004), 3-60.
37. P. Pels, E. Ozturk-Isik, M.G. Swanson, L. Vanhamme, J. Kurhanewicz, S.J. Nelson and S. Van Huffel, Quantification of prostate MRSI data by model-based time domain fitting and frequency domain analysis, NMR Biomed 19(2) (2006), 188-197.
38. U. Pilatus, E. Ackerstaff, D. Artemov, N. Mori, R.J. Gillies and ZM. Bhujwalla, Imaging prostate cancer invasion with multi-nuclear magnetic resonance methods: The Metabolic Boyden Chamber, Neoplasia 2 (3) (2002), 273-279, (New York, NY).
39. F Podo, Tumour Phospholipid Metabolism, NMR in Biomedicine 12 (1999), 413-439.
40. D. Pucar, J.A, Koutcher, A. Shah, J.P. Dyke, L. Schwartz, H. Thaler, J. Kurhanewicz, P.T. Scardino, W.K. Kelly, H. Hricak and K.L. Zakian, Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse, Clin Prostate Cancer 3(3) (2004), 174-181.
41. D. Pucar, A. Shukla-Dave, H. Hricak, C.S. Moskowitz, K. Kuroiwa, S. Olgac, L.E. Ebora, P.T. Scardino, J.A. Koutcher and K.L. Zakian, Prostate cancer: Correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience, Radiology 236(2) (2005), 545-553.
42. W.A. Sakr, M.V. Tefilli, D.J. Grignon, M. Banerjee, J. Dey, E.L. Gheiler, R. Tiguert, I.J. Powell and D.P. Wood, Gleason score 7 prostate cancer: A heterogeneous entity? Correlation with pathologic parameters and disease-free survival, Urology 56(5) (2000), 730-734.
43. T.W. Scheenen, D.W. Klomp, S.A. Roll, J.J. Futterer, J.O. Barentsz and A. Heerschap, Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate, Magn Reson Med 52 (1) (2004), 80-88.
44. J. Scheidler, H. Hricak, D.B. Vigneron, D. Sokolov, L., L.R. Huang, C. Zaloudek, J., P.R. Carroll and J. Kurhanewicz, Prostate Cancer: Localization with Three-dimensional Proton MR Spectroscopic Imaging - Clinicopathologic Study, Radiology 213(2) (1999), 473-480.
45. F. Schick, H. Bongers, S. Kurz, W.-I. Jung, M. Pfeffer and O. Lutz, Localized Proton MR Spectroscopy of Citrate in Vitro and of the Human Prostate in Vivo at 1.5T, Magn Reson Med 29(1) (1993), 38-43.
46. M. Schnall, R. Lenkinski, B. Milestone and H. Kressel, Localized 1H Spectroscopy of the Human Prostate in vivo, New York, 1990, 288.
47. A.A. Schricker, J.M. Pauly, J. Kurhanewicz, M.G. Swanson and D.B. Vigneron, Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging, Magn Reson Med 46(6) (2001), 1079-1087.
48. A. Shukla-Dave, H. Hricak, C. Moskowitz, N. Ishill, A. Oguz, K. Kuroiwa, J. Spector, M. Kumar, V.E. Reuter, J.A. Koutcher and K.L. Zakian, Detection of Prostate Cancer by MR Spectroscopic Imaging: An Expanded Paradigm Incorporating Polyamines, Radiology 245(2) (Nov 2007), 499-506.
49. J. Star-Lack, S.J. Nelson, J. Kurhanewicz, L.R. Huang and D.B. Vigneron, Improved Water and Lipid Suppression for 3D PRESS CSI Using RF Band Selective Inversion with Gradient Dephasing (BASING), Magn Reson Med 38(2) (1997), 311-321.
50. M.G. Swanson, D.B. Vigneron, Z.L. Tabatabai, R.G. Males, L. Schmitt, P.R. Carroll, J.K. James, R.E. Hurd and J. Kurhanewicz, Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/ 3D-MRSI-targeted postsurgical prostate tissues, Magn Reson Med 50(5) (2003), 944-954.
51. M.G. Swanson, D.B. Vigneron, T.K. Tran, N. Sailasuta, R.E. Hurd and J. Kurhanewicz, Single-voxel oversampled J-resolved spectroscopy of in vivo human prostate tissue, Magn Reson Med 45(6) (2001), 973-980.
52. M.G. Swanson, A.S. Zektzer, Z.L. Tabatabai, J. Simko, S. Jarso, K.R. Keshari, L. Schmitt, P.R. Carroll, K. Shinohara, D.B. Vigneron and J. Kurhanewicz, Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy, Magn Reson Med 55(6) (2006), 1257-1264.
53. T. Tran, D. Vigneron, N. Sailasuta, J. Tropp, P. Le Roux, J. Kurhanewicz, S. Nelson and R. Hurd, Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer, Magn Reson Med 43(1) (2000), 23-33.
54. M. van der Graaf, R.G. Schipper, G.O. Oosterhof, J.A. Schalken, A.A. Verhofstad and A. Heerschap, Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer, MAGMA 10(3) (2000), 153-159.
55. D.B. Vigneron, R. Males, S. Noworolski, S.J. Nelson, J. Scheidler, D. Sokolov, H. Hricak, P. Carroll and J. Kurhanewicz, 3D MRSI of Prostate Cancer: Correlation with Histologic Grade, Proc. ISMRM 6th Annual Mtg., Sydney, 1998, 488.
56. A.E. Wefer, H. Hricak, D.B. Vigneron, F.V. Coakley, Y. Lu, J. Wefer, U. Mueller-Lisse, P.R. Carroll and I. Kurhanewicz, Sextant localization of prostate cancer: Comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology, J Urol 164(2) (2000), 400-404.
57. K.K. Yu, J. Scheidler, H. Hricak, D.B. Vigneron, C.J. Zaloudek, R.G. Males, S.J. Nelson, P.R. Carroll and J. Kurhanewicz, Prostate Cancer: Prediction of Extracapsular Extension with Endorectal MR Imaging and Three-dimensional Proton MR Spectroscopic Imaging, Radiology 213(2) (1999), 481-488.
58. M. Zaider, E.K. Lee, K.L. Zakian, H.I. Amols, J. Dyke, G. cohen, M.J. Zelefsky and J.A. Koutcher, Intensity modulated conformal treatment planning for prostate implants using MR spectroscopy imaging, Int J Rad Onc Biol Phys 47(4) (2000), 1085-1096.
59. K.L. Zakian, S. Eberhardt, H. Hricak, A. Shukla-Dave, S. Kleinman, M. Muruganandham, K. Sircar, M.W. Kattan, V.E. Reuter, P.T. Scardino and J.A. Koutcher, Transition zone prostate cancer: Metabolic characteristics at 1H MR spectroscopic imaging - initial results, Radiology 229(1) (2003), 241-247.
60. K.L. Zakian, K. Sircar, H. Hricak, H.N. Chen, A. Shukla-Dave, S. Eberhardt, M. Muruganandham, L. Ebora, M.W. Kattan, V.E. Reuter, P.T. Scardino and J.A. Koutcher, Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy, Radiology 234(3) (2005), 804-814.